Literature DB >> 32694054

Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.

Philip H Pucher1, Saqib A Rahman2, Robert C Walker2, Ben L Grace2, Andrew Bateman3, Tim Iveson3, Andrew Jackson3, Charlotte Rees3, James P Byrne2, Jamie J Kelly2, Fergus Noble2, Timothy J Underwood2.   

Abstract

BACKGROUND: Esophageal cancer is increasingly common and carries a poor prognosis. The optimal treatment modality for locally advanced cancer is unknown, with current guidance recommending either neoadjuvant chemotherapy (CT) or chemoradiotherapy (CRT) followed by surgery. There is a lack of adequately powered trials comparing CT against CRT. We retrospectively compared CT versus CRT using a propensity score weighting approach.
METHODS: Demographic, disease, treatment and outcome data were retrieved from a local database for patients who received neoadjuvant CT or CRT followed by surgery. Inverse probability of treatment weighting (IPTW) was used to balance groups using a propensity score-weighting approach. Groups were assessed for differences in postoperative outcomes and survival. Kaplan-Meier and non-parametric tests were used to compare survival and outcome data as appropriate.
RESULTS: Data for 284 patients were retrieved. Following IPTW groups were well matched. No significant differences were seen for postoperative complications (CT 64.9% vs. CRT 63.3%, p = 0.807), including major complications (24.0% vs. 23.6%, p = 0.943) and anastomotic leak (7.8% vs. 5.6%, p = 0.526). Significantly higher rates of clinical regression and complete pathological response were seen following CRT (p = 0.002 for both). Rates of R0 resection were higher with CRT, CT 79.1% vs. CRT 93.1%, p = 0.006. There was no difference between groups for overall or disease-free survival.
CONCLUSION: This study suggests that the significant improvements in local tumour response seen after neoadjuvant CRT compared to CT may not translate to different survival outcomes. However, it must be stressed that adequately powered prospective trials are still lacking.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Adenocarcinoma; Chemotherapy; Gastroesophageal; Neoadjuvant; Radiotherapy

Mesh:

Substances:

Year:  2020        PMID: 32694054     DOI: 10.1016/j.ejso.2020.06.038

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  3 in total

1.  Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study.

Authors:  Jiayue Ye; Sheng Hu; Wenxiong Zhang; Deyuan Zhang; Yang Zhang; Dongliang Yu; Jinhua Peng; Jianjun Xu; Yiping Wei
Journal:  Front Surg       Date:  2022-05-06

2.  Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal squamous cell cancer: A meta-analysis.

Authors:  Yaru Guo; Mingna Xu; Yufei Lou; Yan Yuan; Yuling Wu; Longzhen Zhang; Yong Xin; Fengjuan Zhou
Journal:  PLoS One       Date:  2022-08-05       Impact factor: 3.752

3.  RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.

Authors:  Sylvie Lorenzen; Alexander Biederstädt; Ulrich Ronellenfitsch; Christoph Reißfelder; Stefan Mönig; Frederik Wenz; Claudia Pauligk; Martin Walker; Salah-Eddin Al-Batran; Bernhard Haller; Ralf-Dieter Hofheinz
Journal:  BMC Cancer       Date:  2020-09-15       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.